Shandwick to help launch oral diabetes treatment

Biotechnology company Cortecs, which made headlines last week with its new oral drug for insulin, has hired Shandwick to handle its medical and financial PR. The account covers the UK, Europe and the US.

Biotechnology company Cortecs, which made headlines last week with

its new oral drug for insulin, has hired Shandwick to handle its medical

and financial PR. The account covers the UK, Europe and the US.



Shandwick will replace Buchanan Communications and Brandon Harris and

Co, which handled trade and financial PR in the UK, and Keyhoe White

Savage, which handled investor relations in the US.The account is

estimated to worth at least pounds 100,000.



Cortecs made national news last week with an announcement that it has

developed oral versions of drugs including insulin. Its research means

drugs to treat diabetes and osteoporosis will no longer have to be

injected.



The market for these drugs is believed to be worth in excess of pounds

1.6 billion.



This has prompted Cortecs to review its PR, as has the fact that it is

about to transfer its primary listing from Australia to the London Stock

Exchange, which means it will make financial announcements in the UK,

rather than Australia. Shandwick’s London office will handle financial

PR, as well as investor relations and medical trade PR in Europe. The

agency’s New York office will handle investor and trade PR in the

US.



Shandwick’s hiring follows the appointment of a full time head of

corporate communications for Cortecs. John Barrington-Carver, who has

been advising the company on a freelance, part-time basis for just over

three years, started working full time in July. He continues to work on

a freelance basis.



Shandwick used to work for another biotechnology firm - Chiroscience -

until it lost the account this summer.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.